What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide: a chain of 15 amino acids, derived from a partial sequence of the human gastric juice protein BPC. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. CAS 137525-51-0, molecular weight approximately 1,419 Da. It is classified as a cytoprotective research peptide and has been the subject of peer-reviewed investigation for over three decades.
The proline-rich sequence of BPC-157 confers structural rigidity that makes it unusually resistant to proteolytic degradation compared to most peptides of comparable length. This stability, documented in animal model pharmacokinetics, makes it a tractable tool for studying multi-system cytoprotective pathways in controlled laboratory settings. BPC-157 is available from Lone Star Peptide Co. as a lyophilized powder verified at ≥99% HPLC purity with LC-MS identity confirmation.
The Nitric Oxide System, Primary Signaling Interface
The nitric oxide (NO) pathway is the most extensively characterized signaling interface for BPC-157 in the published literature. Research in rodent models has documented interactions with both endothelial NOS (eNOS) and neuronal NOS (nNOS) pathways. Studies examine how BPC-157 modulates NO production in vascular endothelium and its downstream effects on vasoprotection and tissue homeostasis signaling.
The NO system serves as a convergence point for multiple downstream effects observed in BPC-157 research. Upregulation of eNOS activity in endothelial cell models is associated with vasodilation and angiogenic signaling, both of which appear as downstream readouts in published BPC-157 studies examining vascular responses in gastrointestinal and musculoskeletal tissue models.
BPC-157 literature spans both in vitro cell culture studies and in vivo rodent models. Researchers designing new experiments should note that observed pathway interactions may differ between cell-free biochemical assays, cell culture systems, and intact animal models. Primary literature should be consulted for dose-response parameters appropriate to each system.
Growth Factor Pathway Interactions
Growth factor receptor interactions represent a second major research domain for BPC-157. Published studies have examined interactions with the EGF receptor, VEGF signaling, and growth hormone receptor pathways. The compound has been shown to upregulate VEGF expression in wound healing models and to interact with the GH receptor in ways that modulate downstream IGF-1 signaling, of interest in bone and tendon repair research.
VEGF upregulation is particularly well-documented across multiple tissue contexts. Published experiments in cell culture and rodent models consistently report elevated VEGF expression following BPC-157 treatment, with angiogenic readouts including increased vessel density in tissue sections. These results make BPC-157 a relevant tool for researchers studying angiogenesis as an experimental endpoint.
GABAergic and Dopaminergic System Research
CNS-focused BPC-157 research has examined modulation of GABAergic and dopaminergic neurotransmitter systems. Published studies demonstrate interactions with dopamine receptor signaling, particularly in the context of models examining dopaminergic neurotoxicity. This body of work has generated interest among researchers studying neuroprotective mechanisms in controlled in vitro and rodent experimental systems.
The GABAergic interaction data is less voluminous but represents an active research area. BPC-157's apparent ability to interact with multiple CNS signaling systems simultaneously makes it a complex tool for mechanistic research, researchers should design controls accordingly to isolate specific pathway contributions.
Inflammatory Cytokine Cascade Modulation
Published research has examined BPC-157's effects on inflammatory cytokine cascades, with particular focus on NF-κB pathway interactions. NF-κB is a central regulatory hub for pro-inflammatory cytokine expression, and compounds that modulate this pathway are of substantial research interest across multiple disease model categories. BPC-157 has been shown in published models to attenuate NF-κB activation under inflammatory challenge conditions, with downstream reductions in TNF-α, IL-1β, and IL-6 expression.
For researchers working in inflammation biology, this makes BPC-157 a relevant comparative tool alongside established pathway modulators. Its multi-target profile means that inflammation readouts in BPC-157 experiments will reflect interactions across the NO, growth factor, and cytokine systems simultaneously, requiring appropriate experimental design to isolate contributions.
Laboratory Handling and Reconstitution
BPC-157 is supplied as a lyophilized white powder and is readily soluble in sterile water, phosphate-buffered saline (PBS), and dilute acetic acid solutions. Reconstitution should be performed by adding solvent gently along the vial wall without vortexing. For cell culture applications, sterile-filtered reconstitution vehicles are required.
Storage of the lyophilized powder is at −20°C, protected from moisture and light. Reconstituted solutions are stable at 4°C for up to 7 days. For longer storage, aliquot into single-use volumes at −20°C to avoid freeze-thaw degradation. The proline-rich backbone makes BPC-157 more stable in solution than many comparable peptides, but standard peptide storage protocols remain essential for integrity. See our peptide storage mistakes guide for the most common errors to avoid.
| Parameter | Value | Notes |
|---|---|---|
| CAS Number | 137525-51-0 | Confirmed by LC-MS |
| Molecular Weight | ~1,419 Da | 15 amino acid sequence |
| Purity (HPLC) | ≥99% | Third-party verified |
| Solubility | Water, PBS, dilute AcOH | Good aqueous solubility |
| Storage (lyophilized) | −20°C | Protected from moisture |
| Solution stability | 7 days at 4°C | Single-use aliquots preferred |
Research Context and Literature
The BPC-157 literature is unusually extensive for a synthetic research peptide, with primary research originating predominantly from Croatian research institutions and spanning over four decades. This body of work includes in vitro cell culture studies, acute and chronic rodent models across multiple organ systems, and mechanistic pharmacology studies examining pathway interactions at molecular resolution.
Researchers entering this field have access to a rich primary literature through PubMed. The compound's multi-pathway activity profile makes it particularly valuable for researchers studying cytoprotection as an integrated biological phenomenon. For tissue repair studies, TB-500 is frequently studied alongside BPC-157: the two compounds address complementary mechanistic pathways and are available together as the Wolverine Blend for researchers investigating combined pathway effects.
Frequently Asked Questions
FOR RESEARCH USE ONLY. All compounds referenced in this article are supplied exclusively for in vitro and laboratory research by qualified scientists. Not intended for human or animal consumption, therapeutic use, or clinical application. This article is provided for scientific and educational purposes only. Lone Star Peptide Co. makes no therapeutic claims regarding any compound referenced herein.